Supreme Court Report

Supreme Court of the United States · Official docket →

GlaxoSmithKline, LLC, et al. v. Superior Court of California, Alameda County

Paid petition · Court of Appeal of California, First Appellate District, No. A166778 · judgment October 23, 2023


Certiorari denied · October 7, 2024
Pre-decision estimate: 4% cert probability

Before the decision, roughly the 4.1% base rate. The model weighted this up for counsel with five or more prior petitions here, a dissent in the court below (flagged in the petition), and a business petitioner.

Question presented

Andrew T. Bayman Matthew J. Blaschke KING & SPALDING LLP Rachel S. Rubens 1180 Peachtree Street, KING & SPALDING LLP Suite 1600 50 California Street, Atlanta, GA 30309 Suite 3300 Telephone: (404) 572-4600 San Francisco, CA 94111 Facsimile: (404) 572-5100 Telephone: (415) 318-1212 abayman@kslaw.com Facsimile: (415) 318-1300 mblaschke@kslaw.com rrubens@kslaw.com Counsel for Boehringer Ingelheim Pharmaceuticals, Inc. and Boehringer Ingelheim USA Corporation Joseph G. Petrosinelli Amy Mason Saharia Jessica B. Rydstrom WILLIAMS & CONNOLLY LLP 680 Maine Avenue, SW Washington, DC 20024 Telephone: (202) 434-5000 Facsimile: (202) 434-5029 jpetrosinelli@wc.com asaharia@wc.com jrydstrom@wc.com Counsel for Pfizer, Inc.

Counsel of record

For petitioner
Jay Philip Lefkowitz
Kirkland & Ellis LLP

For respondent

Case

Conference history
Distributed for 1 conference

Amicus briefs
1 cert-stage

Linked docket
23A836

Proceedings

  1. Oct 07 2024
    Petition DENIED.
  2. Aug 07 2024
    DISTRIBUTED for Conference of 9/30/2024.
  3. Jul 18 2024
    Brief amicus curiae of The Chamber of Commerce of the United States of America filed.
  4. Jun 14 2024
    Petition for a writ of certiorari filed. (Response due July 18, 2024)
  5. Mar 13 2024
    Application (23A836) granted by Justice Kagan extending the time to file until June 15, 2024.
  6. Mar 08 2024
    Application (23A836) to extend the time to file a petition for a writ of certiorari from April 16, 2024 to June 15, 2024, submitted to Justice Kagan.